Isavuconazole in Critically Ill Patients: Efficacy and Safety

Isavuconazole in Critically Ill Patients: A Study on Antifungal Efficacy and Safety

Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in healthy individuals, exhibiting significant variability.

This study aims to explore the variability of isavuconazole plasma concentrations in critically ill patients and its correlation with efficacy and adverse effects. The research includes:

1. The distribution and variability of isavuconazole plasma concentrations in critically ill patients;
2. Clinical outcomes;
3. Adverse effects.

Inclusion Criteria:

• Adult critically ill patients (≥18 years) admitted to ICU with suspected or confirmed invasive fungal infection (IFI)
• IFI diagnosis per EORTC/MSGERC 2019 criteria

Exclusion Criteria:

• Drug allergy
• Inherited short QT syndrome
• Contraindications for nasogastric/oral drug delivery
• <18 years old